EntryPoint Capital’s Pliant Therapeutics PLRX Stock Holding History

EntryPoint Capital’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-18,323	Closed	-$241K	–	891
2024 Q4	$241K	Buy	18,323 +2,412	+15%	+$32.9K	0.1%	495
2024 Q3	$178K	Buy	+15,911	New	+$199K	0.1%	495
2024 Q2	–	Sell	-20,006	Closed	-$298K	–	1458
2024 Q1	$298K	Buy	20,006 +9,992	+100%	+$165K	0.27%	29
2023 Q4	$181K	Buy	+10,014	New	+$152K	0.17%	118

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

EntryPoint Capital's PLRX Position: Q1 2025 in Review

EntryPoint Capital sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 18,323 shares — an estimated $241K sold.

EntryPoint Capital first reported a position in PLRX in Q4 2023 and held it in 4 quarters. The position peaked at $298K in Q1 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

EntryPoint Capital reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
EntryPoint Capital sold 18,323 Pliant Therapeutics shares in Q1 2025, an estimated $241K.
EntryPoint Capital first reported a position in Pliant Therapeutics in Q4 2023 and held it in 4 quarters.
EntryPoint Capital's Pliant Therapeutics position peaked at $298K in Q1 2024.
140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.